OR-LATTICE-SEMICONDUCTOR
23.6.2021 18:02:13 CEST | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice CertusPro™-NX general purpose FPGA family. As the fourth device family based on the Lattice Nexus™ platform to be launched in just 18 months, CertusPro-NX continues Lattice’s commitment to FPGA innovation with leadership power efficiency, the highest bandwidth in the smallest form factor in comparison to similar devices, and as the only FPGAs in their class with support for LPDDR4 external memory. With advanced performance capabilities and the highest logic density currently available on a Nexus-based device, CertusPro-NX FPGAs are designed to accelerate application development for the Communications, Compute, Industrial, Automotive, and Consumer markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005270/en/
“Many Edge devices require low power consumption for better thermal management, high system bandwidth for fast chip-to-chip communication, components with small form factors for compact device designs, robust memory resources to support data processing, and high reliability for mission-critical applications,” said Linley Gwennap, Principal Analyst at The Linley Group. “Lattice’s CertusPro-NX FPGAs address all of these factors; in particular, they far exceed the competition in mean time between failures (MTBF) and offer the lowest power in their class.”
“At Lattice, we are constantly looking for ways to innovate and design products based on the needs of our customers, and Lattice CertusPro-NX FPGAs are the latest example of how we’re delivering on this commitment,” said Gordon Hands, Senior Director of Product Marketing, Lattice Semiconductor. “The performance and differentiated features we’ve designed into CertusPro-NX deliver capabilities that were previously unavailable in low power FPGAs to support the next generation of Edge applications that OEMs are eager to provide to customers.”
CertusPro-NX FPGAs are designed to enable customer innovation in a wide range of applications, including data co-processing in intelligent systems, high-bandwidth signal bridging in 5G communications infrastructure, and sensor interface bridging in ADAS systems. Key features of the Lattice CertusPro-NX FPGA family include:
- Class-leading power efficiency – By leveraging Lattice’s innovations in FPGA fabric architecture and a low power FD-SOI manufacturing process, CertusPro-NX devices deliver exceptional performance while consuming up to four times less power than competing FPGAs of a similar class.
- Best-in-class system bandwidth – With support for up to eight programmable SERDES lanes capable of speeds up to 10.3 Gbps, CertusPro-NX FPGAs deliver the highest system bandwidth in their class to enable popular communication and display interfaces like 10 Gigabit Ethernet, PCI Express, SLVS-EC, CoaXPress, and DisplayPort.
- Optimized Edge processing – To meet demand for robust data co-processing in Edge AI and ML applications, CertusPro-NX FPGAs feature up to 65 percent more available on-chip memory than other similar FPGAs. CertusPro-NX devices are the only low power FPGAs currently supporting the LPDDR4 DRAM memory standard, which is preferred due to its projected long-term availability.
- High logic density - With support for up to 100k logic cells, CertusPro-NX FPGAs currently offer the highest logic density of any Nexus-based FPGA.
- Industry-leading reliability – Mission-critical automotive, industrial, and communications applications must deliver high availability to enable predictable performance and keep users safe. Thanks to innovations in the Lattice Nexus platform, CertusPro-NX devices are up to 100 times more resistant to soft errors.
- Smallest-in-class form factor – With a design footprint of 81 mm2 , CertusPro-NX FPGAs are up to 6.5 times smaller than competing devices. Small form factor is a key design consideration for developers of industrial cameras or the SFP modules used in communication systems.
CertusPro-NX is compatible with the latest version of the Lattice Radiant® design software also announced today. Lattice has already shipped CertusPro-NX samples to select customers. For more information about the technologies mentioned above, please visit:
- www.latticesemi.com/CertusPro-NX
- www.latticesemi.com/LatticeNexus
- www.latticesemi.com/LatticeRadiant
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
